Home/Health Plans/Employers/OnTrak Members/Contact Us
/
         
Blog Home  
  » Home  
  Recent Posts  
 
 
 
  Blog Calendar  
 
SuMoTuWeThFrSa
      1
23
4
5678
910111213
14
15
16
17
1819202122
23242526272829
30      
 
  Catasys Newsletter  
  Get the latest in healtcare news. » Sign Up Now  

Welcome to the Catasys On Healthcare Blog
Substance dependence drives significant health care costs for payors through a combination of factors that include acute inpatient utilization and unaddressed co-morbidities. The Substance Dependence problem is pervasive, largely untreated and costly. Stay informed on these topics by visiting our blog periodically. You can also sign up for the Catasys On Healthcare Newsletter to receive the latest in health care news. » Sign Up for Newsletter


Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy of Flumazenil and Gabapentin in Reducing Craving and Use During use during Initial Treatment of Methamphetamine Dependence

Catasys Health - Wednesday, November 25, 2009

Harold Urschel, Research Across America, Dallas, Texas
Published in the Journal of Psychopharmacology, November 25, 2009
 » More


Raymond Anton, Medical University of South Carolina, Charleston, SC

Catasys Health - Saturday, August 01, 2009

Randomized, Stratified, Double-Blind, Placebo-Controlled Trial of Flumazenil and Gabapentin for the Treatment of Alcohol Dependence
Published in the Journal of Clinical Psychopharmacology, August 2009; 29(4):334-342.

 The OnTrak Medical Treatment Program achieved a significant reduction in use and cravings among members with symptoms of alcohol withdrawal (>6 CIWA) when compared to placebo.

Among members with more symptoms of alcohol withdrawal, the Prometa group experienced: » More
| 1 |

 
 
  Tags
 
opioid SD health insurance addict addiction alcohol dependence hydrocodone ADHD heroin methamphetamine dependence dependence issues hospital alcoholism facebook craving score Harold Urschel methamphetamine OnTrak opiod abuse double-blind smoking naloxone mental illness flumazenil urine drug screen narcotic data mining high-utilizing pain killers OxyContin opiod-based behavioral health drug treatment drug overdose relapse marijuana primary care behavioral health care services painkillers medical methadone stratified meth Catasys medical costs trauma drinking predictive modeling drug addicts placebo sober opioid-drug interactions behavioral healthcare ADD Health Care Utilization alcohol drinking withdrawal depression screening sugar UnitedHealthcare opiates oxycodone health plan substance dependence costs cocaine drug use suboxone hospitalizations behavioral healthcare services pain pills morphine anxiety reduction in craving pain medication substance dependence health insurance substance dependence vicodin contract communication social network Co Occurring Disorders fentanyl percocet health insurance muscle relaxant health reform placebo-controlled opioid abuse depression cocaine treatment cigarettes vivitrol Opioid Medications Opioid Treatment identification care coaching gabapentin Journal of Psychopharmacology substance use disorder nicotine drug abuse prometa PTSD craving medical and behavioral costs stress overdose psychosocial reducing craving opioid overdose chronic pain recovery post-traumatic stress disorder reduction in use prescriptions SD members treatment buprenorphine Opioid Prescribing behavioral health care ER sobriety codeine mental health randomized CIWA addiction treatment Raymond Anton drug addiction binge drinking alcohol physician- patient relations bipolar disorder diabetes opioid antagonist emergency room Research Across America stimulants over-the-counter substances recovery network alcohol treatment relapse prevention
  Call Us Today
  866-517-1414
         
 
 
Home/News/Press/Investor Relations/Careers/BlogContact Us/Site Index/Privacy Policy/Photo Disclaimer
 
  Copyright © 2013 Catasys. All rights reserved. | 11150 Santa Monica Blvd., Suite 1500, Los Angeles, California 90025 | Toll Free: 1-866-517-1414